CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
cAd3-Marburg vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03475056
NCT03475056Phase 1Completed
CompareCT.gov

RV 507: A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Marburg Chimpanzee Adenovirus Vector Vaccine, VRC-MARADC087-00-VP (cAd3-Marburg), in Healthy Adults

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 23, 2018·Updated Aug 11, 2022

In Brief

A Phase 1 clinical trial evaluating cAd3-Marburg vaccine for Marburg Virus Disease. Completed, enrolled 40 participants across 1 site.

Detailed Summary

RV 507 was a Phase I, open-label study to examine the safety, tolerability and immunogenicity of an investigational Marburg vaccine given by intramuscular (IM) injection to healthy adults. The study was a dose escalation of VRC-MARADC087-00-VP, a chimpanzee adenovirus serotype 3 (cAd3) vector vaccine, which encodes wild type (WT) glycoprotein (GP) from Marburgvirus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarburg Virus Disease
CountriesUnited States
CollaboratorsUS Military HIV Research Program

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 23, 2018
Enrollment StartOct 9, 2018
Primary CompletionDec 19, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.3 years ago

Interventions

cAd3-Marburg vaccinebiological

The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).